Lilly's Gemzar appeal fails to get Supreme Court hearing

The U.S. Supreme Court has turned away Eli Lilly's appeal in a dispute over the company's patent on the cancer drug Gemzar, leaving intact a lower-court ruling that opened the door to generic competition. Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.